On paper, CBD and THC are almost twins: same chemical formula (C₂₁H₃₀O₂), same source plant (Cannabis sativa), same family (cannabinoids). And yet their effects are opposite. Here are the 7 differences documented by science, and why they matter.
1. The 3D structure: one detail changes everything
CBD and THC share the exact same molecular formula: 21 carbon atoms, 30 hydrogen, 2 oxygen. Their only difference? The spatial arrangement.
- THC: closed cyclic structure. The molecule fits perfectly into the brain's CB1 receptor, like a key into a lock.
- CBD: open cyclic structure (a free phenyl ring). The key doesn't fit the CB1 lock — but it changes the lock's shape.
This single difference in atomic arrangement separates a psychoactive compound from a non-psychoactive one.
2. Action on the brain
THC: direct CB1 agonist
THC binds directly to cannabinoid CB1 receptors, abundant in the prefrontal cortex, hippocampus, cerebellum. This binding produces:
- Euphoria / "high"
- Time distortion
- Appetite stimulation
- Also: anxiety, paranoia, short-term memory impairment
CBD: CB1 allosteric antagonist
CBD doesn't bind to the primary site of CB1, but to an allosteric site (a secondary site). It modifies the receptor's shape without activating it, which:
- Reduces THC binding effectiveness
- Produces no psychoactive effect
- Modulates the endocannabinoid system without overactivating it
Practical consequence: CBD calms without getting you high. THC gets you high but can panic you.
3. Effects experienced
| Effect | THC | CBD | |---|---|---| | Psychoactive "high" | ✓ strong | ✗ none | | Muscle relaxation | ✓ | ✓ | | Anxiety reduction | ± (low dose) / ✗ (high) | ✓ (demonstrated) | | Appetite stimulation | ✓ strong | ✗ neutral | | Dry mouth | ✓ | mild | | Red eyes | ✓ | ✗ | | Short-term memory issues | ✓ | ✗ | | REM sleep disruption | ✓ (suppresses REM) | ± (may increase REM) |
4. Legality
THC: scheduled narcotic worldwide, except medical use frameworks (Germany, Netherlands, some US states). In France, possession is illegal — up to 1 year imprisonment and €3,750 fine.
CBD: authorised everywhere in Europe. In the US, legal at federal level since the 2018 Farm Bill. WHO 2018: "CBD shows no potential for abuse and is not likely to pose a public health concern."
5. Dependence risk
- THC: moderate addictive potential. About 9 % of users develop dependence (INSERM 2021 figure). Characterised withdrawal (irritability, sleep disturbances).
- CBD: no documented addictive potential. No withdrawal syndrome, no significant tolerance.
6. Side effects
THC side effects
- Short-term: anxiety, paranoia, tachycardia, immediate memory loss
- Long-term (chronic use): cognitive impairment, amotivational syndrome, psychotic risk in genetically predisposed individuals
CBD side effects
- Short-term: drowsiness (at high dose), mild dry mouth, diarrhoea (rare, at pharmacological doses > 300 mg/day)
- Long-term: no harmful effects documented in 1-year studies (Bergamaschi 2011, Iffland 2017)
Notable interaction: CBD inhibits hepatic enzymes CYP3A4 and CYP2C19. It may increase blood concentrations of some medicines (warfarin, certain antiepileptics). Inform your doctor if you take chronic treatment.
7. Recognised medical uses
THC: authorised in France via Sativex (multiple sclerosis) and the 2021-2024 medical cannabis experiment (5 indications). Conditions: refractory chronic pain, chemotherapy nausea, AIDS anorexia.
CBD: authorised via Epidyolex since 2019 for 3 forms of pharmaco-resistant epilepsy (Dravet, Lennox-Gastaut, tuberous sclerosis complex). Clinical studies ongoing for: social anxiety, schizophrenia, neuropathic pain, addiction.
In summary
Same plant, but two opposite logics:
- THC = key that fits the lock → powerful but risky effects
- CBD = key that modifies the lock → mild and well-tolerated effects
CBD, in 2026, is the legal, non-psychoactive molecule for which clinical sciences recognise documented benefits on anxiety, sleep, epilepsy and inflammation. THC remains controlled for public health reasons.
Scientific sources
- World Health Organization. Cannabidiol (CBD) Critical Review Report. ECDD 2018.
- Englund A et al. "Cannabidiol inhibits THC-elicited paranoid symptoms..." J Psychopharmacol. 2013.
- Iffland K, Grotenhermen F. "An update on safety and side effects of cannabidiol" Cannabis and Cannabinoid Research. 2017.
- Bergamaschi MM et al. "Safety and side effects of cannabidiol..." Curr Drug Saf. 2011.
- ANSM. Medical cannabis evaluation report 2024.